Uncategorized

Skyhawk CEO hopes FDA’s new uniQure position will translate to Huntington’s pill

Published

on

A recent FDA reversal sparked new hope for patients with Huntington’s disease. Flying under the radar, Skyhawk Therapeutics revealed 12-month functional data from a midstage trial of its own candidate showing improvements on a key disease measurement scale.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version